Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202265 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1PIK3CDCHRM5 | |
| SCHEMBL10284339 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1PIK3CDCHRM5 | |
| SCHEMBL24220956 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1PIK3CDCHRM5 | |
| SCHEMBL21454476 | 0.94 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1CHRM5CHRM3 | |
| SCHEMBL18623939 | 0.94 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1CHRM5CHRM3 | |
| SCHEMBL14328746 | 0.92 | HSD17B10 (0.41) | HSD17B10SLC6A9S1PR1ALDH1A1KDM4E | |
| SCHEMBL29299640 | 0.92 | HSD17B10 (0.41) | HSD17B10SLC6A9S1PR1PIK3CDCHRM5 | |
| SCHEMBL29299643 | 0.92 | HSD17B10 (0.41) | HSD17B10SLC6A9S1PR1PIK3CDCHRM5 | |
| SCHEMBL21454477 | 0.92 | HSD17B10 (0.44) | HSD17B10SLC6A9CHRM5CHRM3SIGMAR1 | |
| SCHEMBL20438446 | 0.91 | PIK3CD (0.40) | HSD17B10PIK3CDCHRM5CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | HSD17B10 3607/4885SLC6A9 4564/4885S1PR1 397/4885 |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | PSMA1, ALB, PSMA2 | HSD17B10 3053/4885SLC6A9 562/4885S1PR1 984/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | HSD17B10 3607/4885SLC6A9 4564/4885S1PR1 397/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | HSD17B10 3449/4885SLC6A9 4366/4885S1PR1 1958/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | HSD17B10 2957/4885SLC6A9 705/4885S1PR1 2346/4885 |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | PSMA1, ALB, PSMA2 | HSD17B10 3053/4885SLC6A9 562/4885S1PR1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.